Segment-wise, Glucosamine represents the largest segment for chitin derivatives. Glucosamine is the most widely used ingredient in joint health medications. A majority of neutraceuticals formulated for joint health problems contain glucosamine/chondroitin mixture. However, with several food and beverage companies including glucosamine in their products, demand for glucosamine usage is no longer confined to the joint health segment. Chitosan is also a significant chitin derivative with numerous end-use applications. Out of the varied end-use applications of chitosan, water treatment accounts for the largest share of consumption. The end-use application is likely to retain its prominence over the analysis period, however, consumption of the biopolymer in medical/healthcare, agrochemicals, food & beverages and textile finishing is expected to pick up pace. The fastest CAGR is anticipated in agrochemicals at 17.6% from 2010 through 2018.
Major players profiled in the report include Advanced Biopolymers AS, CarboMer Inc., Heppe Medical Chitosan GmbH, Kunpoong Bio Co. Ltd., Meron Biopolymers, Primex Ehf, and Zhejiang Candorly Pharmaceutical Co., Ltd.
An Executive Summary for this report and free sample pages from the full document are available at http://www.giiresearch.com/report/go138693-chitin-chitosan.html
The global market for fatty esters is forecast to reach $2.2 billion by 2018. The US represents the largest regional market for fatty esters worldwide, as stated by the new market research report on Fatty Esters. Europe trails the US in terms of the sales of fat
|SOURCE Global Information, Inc.|
Copyright©2012 PR Newswire.
All rights reserved